Trial Profile
A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Asunercept (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors CANbridge Life Sciences; CANbridge Pharmaceuticals
- 28 Mar 2023 According to a CANbridge Pharmaceuticals media release, data from this trial were presented at the ESMO Sarcoma and Rare Cancers Annual Meeting
- 17 Mar 2023 Long-term follow up data results published in the CANbridge Pharmaceuticals Media Release.
- 13 Mar 2023 According to a CANbridge Pharmaceuticals media release, an abstract on the long-term follow up data from the CAN008 Phase 1/2 trial in glioblastoma multiforme has been accepted for a poster presentation by the European Society for Medical Oncology (ESMO) Sarcoma and Rare Cancers Annual Congress.